Evidence map›Paper›PMID 30026870›Full record

ArticleTheranostics2018

Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.

Michael Chavez, Matthew T Silvestrini, Elizabeth S Ingham, Brett Z Fite, Lisa M Mahakian, Sarah M Tam, Asaf Ilovitsh, Arta M Monjazeb, William J Murphy, Neil E Hubbard and 4 more

Open access · goldAbstract read
In one paragraph

Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Sex parity in stimulation of murine lymphocyte trafficking in response to fever-range systemic thermal therapy.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. 7-nm MnTheranostics · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Analysis of Antibody Induction by Macrophages TreatedReports of biochemistry & molecular biology · 2023
    Article
  18. Article
  19. Article
  20. Magic bubbles: utilizing histotripsy to modulate the tumor microenvironment and improve systemic anti-tumor immune responses.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2023
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Michael ChavezUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Matthew T SilvestriniUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Elizabeth S InghamUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Brett Z FiteUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Lisa M MahakianUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Sarah M TamUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Asaf IlovitshUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
Arta M MonjazebUniversity of California, Davis, Department of Radiation Oncology, 4501 X Street, Sacramento, CA 95817.
William J MurphyUniversity of California, Davis, Department of Dermatology, 2921 Stockton Blvd., Institute for Regenerative Cures, Suite 1630, Sacramento, CA 95817, USA.
Neil E HubbardUniversity of California, Davis, Center for Comparative Medicine, Davis, CA 95616, USA.
Ryan R DavisUniversity of California, Davis School of Medicine, Department of Biochemistry and Molecular Medicine, 4645 Second Avenue, Sacramento, CA 95817, USA.
Clifford G TepperUniversity of California, Davis School of Medicine, Department of Biochemistry and Molecular Medicine, 4645 Second Avenue, Sacramento, CA 95817, USA.
Alexander D BorowskyUniversity of California, Davis, Center for Comparative Medicine, Davis, CA 95616, USA.
Katherine W FerraraUniversity of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA.
University of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Ultrasound imaging and enhanced therapeutic responseR01CA134659 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2009 to 2017
$4.4M
Large aperture and wideband modular ultrasound arrays for the diagnosis of liver cancerR01CA211602 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W, TRAHEY, GREGG E. · 2017 to 2021
$3.3M
Image-guided ultrasound therapy and drug delivery in pancreatic cancerR01CA210553 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2016 to 2020
$3.2M
Optimized ultrasound-enhanced immunotherapyR01CA199658 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2015 to 2019
$2.5M
UC Davis Shared Astrios Cell SorterS10OD018223 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHACKLETT, BARBARA L. · 2015 to 2015
$555k
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR012088 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI CURRY, FITZ-ROY E · 1996 to 1996
–
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA134659NCI NIH HHS R01 CA199658NCI NIH HHS R01 CA210553NCI NIH HHS R01 CA211602NCRR NIH HHS C06 RR012088NCRR NIH HHS S10 RR026825NIH HHS S10 OD018223
6 · The paper itself

Abstract

Both adjuvants and focal ablation can alter the local innate immune system and trigger a highly effective systemic response. Our goal is to determine the impact of these treatments on directly treated and distant disease and the mechanisms for the enhanced response obtained by combinatorial treatments.

Indexed as

Adjuvants, ImmunologicAnimalsCombined Modality TherapyDisease Models, AnimalFlow CytometryGene Expression ProfilingHigh-Intensity Focused Ultrasound AblationImmunotherapyMiceNeoplasmsOligodeoxyribonucleotidesSequence Analysis, DNASequence Analysis, RNATreatment OutcomeAdjuvants, ImmunologicCPG-oligonucleotideOligodeoxyribonucleotidesablationimmunotherapyRNA sequencingT-cell receptor sequencingultrasound

Identifiers

PMID30026870
PMCPMC6037035
OpenAlexW2808638507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.